| Year |
Citation |
Score |
| 2023 |
Lambert J, Di Blasi R, Rabian F, Dourthe ME, Baruchel A, Thiéblemont C, Boissel N, Levy V, Picat MQ, Chevret S. Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data. Hemasphere. 7: e873. PMID 37260917 DOI: 10.1097/HS9.0000000000000873 |
0.495 |
|
| 2023 |
Vanier A, Fernandez J, Kelley S, Alter L, Semenzato P, Alberti C, Chevret S, Costagliola D, Cucherat M, Falissard B, Gueyffier F, Lambert J, Lengliné E, Locher C, Naudet F, et al. Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health. Bmj Evidence-Based Medicine. PMID 36788020 DOI: 10.1136/bmjebm-2022-112091 |
0.592 |
|
| 2022 |
Lambert J, Lengliné E, Porcher R, Thiébaut R, Zohar S, Chevret S. Enriching single-arm clinical trials with external controls: possibilities and pitfalls. Blood Advances. PMID 36534147 DOI: 10.1182/bloodadvances.2022009167 |
0.593 |
|
| 2021 |
Biard L, Bergeron A, Lévy V, Chevret S. Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trials. Contemporary Clinical Trials Communications. 21: 100709. PMID 33511301 DOI: 10.1016/j.conctc.2021.100709 |
0.558 |
|
| 2020 |
Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis JH, Lesieur A, Fortin G, Meslin PA, Yakoub-Agha I, Sujobert P, Dumas PY, Récher C, Lebon D, Berthon C, Michallet M, ... ... Chevret S, et al. A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia. Blood. PMID 32871585 DOI: 10.1182/Blood.2020005524 |
0.341 |
|
| 2020 |
Azabou E, Bao G, Heming N, Bounab R, Moine P, Chevallier S, Chevret S, Resche-Rigon M, Siami S, Sharshar T, Lofaso F, Annane D. Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol. Frontiers in Medicine. 7: 372. PMID 32671084 DOI: 10.3389/Fmed.2020.00372 |
0.535 |
|
| 2020 |
Faucheux L, Resche-Rigon M, Curis E, Soumelis V, Chevret S. Clustering with missing and left-censored data: A simulation study comparing multiple-imputation-based procedures. Biometrical Journal. Biometrische Zeitschrift. PMID 32627864 DOI: 10.1002/Bimj.201900366 |
0.505 |
|
| 2020 |
Bridoux F, Arnulf B, Karlin L, Blin N, Rabot N, Macro M, Audard V, Belhadj K, Pegourie B, Gobert P, Cornec Le Gall E, Joly B, Karras A, Jaccard A, Augeul-Meunier K, ... ... Chevret S, et al. Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000298. PMID 32574117 DOI: 10.1200/Jco.20.00298 |
0.313 |
|
| 2020 |
Zerbit J, Chevret S, Bernard S, Kroemer M, Ablard C, Harel S, Brice P, Madelaine I, Thieblemont C. Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study. Annals of Hematology. PMID 32483668 DOI: 10.1007/S00277-020-04045-Y |
0.323 |
|
| 2020 |
Azoulay E, Zafrani L, Mirouse A, Lengliné E, Darmon M, Chevret S. Clinical phenotypes of critically ill COVID-19 patients. Intensive Care Medicine. PMID 32468086 DOI: 10.1007/S00134-020-06120-4 |
0.3 |
|
| 2020 |
Dumas G, Chevret S, Le Corre M, Lemiale V, Jaber S, Azoulay E. Typology of Published Randomized Controlled Trials investigating initial ventilation strategy in Critically Ill Patients with Acute Respiratory Failure-A methodological review. Chest. PMID 32387523 DOI: 10.1016/J.Chest.2020.03.082 |
0.356 |
|
| 2020 |
Dupont A, Chevret S, Montlahuc C, Resche-Rigon M, Fontaine Y, Allaoua S, Kiladjian JJ, Ghrieb Z. [Satisfaction survey in the clinical investigations center (CIC-1427) in Saint-Louis hospital Paris, France]. Therapie. PMID 32113690 DOI: 10.1016/J.Therap.2020.02.001 |
0.492 |
|
| 2020 |
Peyrony O, Gerlier C, Barla I, Ellouze S, Legay L, Azoulay E, Chevret S, Fontaine JP. Antibiotic prescribing and outcomes in cancer patients with febrile neutropenia in the emergency department. Plos One. 15: e0229828. PMID 32109264 DOI: 10.1371/Journal.Pone.0229828 |
0.314 |
|
| 2020 |
Roussel M, Merlini G, Chevret S, Arnulf B, Stoppa AM, Perrot A, Palladini G, Karlin L, Royer B, Huart A, Macro M, Morel P, Frenzel L, Touzeau C, Boyle EM, et al. A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients. Blood. PMID 32108228 DOI: 10.1182/Blood.2019004369 |
0.346 |
|
| 2019 |
Peffault de Latour R, Chevret S, Ruggeri AL, Suarez F, Souchet L, Michonneau D, Sicre de Fontbrune F, Coman T, Dhedin N, Rubio MT, Nguyen S, Mohty M, Socié G. Romiplostim in Patients undergoing Hematopoietic Stem Cell Transplantation: Results of a Phase I/II multicenter Trial. Blood. PMID 31805185 DOI: 10.1182/Blood.2019000358 |
0.309 |
|
| 2019 |
Cheng GS, Bondeelle L, Gooley T, He Q, Jamani K, Krakow EF, Flowers MED, de Latour RP, Michonneau D, Socié G, Chien JW, Chevret S, Bergeron A. Azithromycin use and increased cancer risk among patients with bronchiolitis obliterans after hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31682980 DOI: 10.1016/J.Bbmt.2019.10.025 |
0.351 |
|
| 2019 |
Dumas G, Demoule A, Mokart D, Lemiale V, Nseir S, Argaud L, Pène F, Kontar L, Bruneel F, Klouche K, Barbier F, Reignier J, Stoclin A, Louis G, Constantin JM, ... ... Chevret S, et al. Center effect in intubation risk in critically ill immunocompromised patients with acute hypoxemic respiratory failure. Critical Care (London, England). 23: 306. PMID 31492179 DOI: 10.1186/S13054-019-2590-7 |
0.353 |
|
| 2019 |
Grafféo N, Latouche A, Le Tourneau C, Chevret S. ipcwswitch: An R package for inverse probability of censoring weighting with an application to switches in clinical trials. Computers in Biology and Medicine. 111: 103339. PMID 31442762 DOI: 10.1016/J.Compbiomed.2019.103339 |
0.652 |
|
| 2019 |
Ouedraogo E, Gottlieb J, de Masson A, Lepelletier C, Jachiet M, Salle de Chou C, Galicier L, Bagot M, Chevret S, Bouaziz JD. Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults. Journal of the American Academy of Dermatology. PMID 30981429 DOI: 10.1016/J.Jaad.2018.03.043 |
0.312 |
|
| 2019 |
Biard L, Darmon M, Lemiale V, Mokart D, Chevret S, Azoulay E, Resche-Rigon M. Center Effects in Hospital Mortality of Critically Ill Patients With Hematologic Malignancies. Critical Care Medicine. PMID 30889024 DOI: 10.1097/Ccm.0000000000003717 |
0.53 |
|
| 2019 |
Sébert M, Renneville A, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin MP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, ... ... Chevret S, et al. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica. PMID 30733271 DOI: 10.3324/Haematol.2018.207118 |
0.369 |
|
| 2019 |
Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, et al. Antilymphocyte Globulin for matched sibling donor transplantation in patients with myelofibrosis. Haematologica. PMID 30655365 DOI: 10.3324/Haematol.2018.201400 |
0.308 |
|
| 2019 |
Paillassa J, Di Blasi R, Chevret S, Bernard S, Darmon M, Meignin V, Deau-Fischer B, Camus V, Casasnovas R, Cartron G, Chaoui D, Delwail V, Feugier P, Fornecker LM, Gyan E, et al. CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria Blood. 134: 2887-2887. DOI: 10.1182/Blood-2019-129532 |
0.334 |
|
| 2019 |
Tomowiak C, Desseaux K, Poulain S, Herbaux C, Perrot A, Mahe B, Morel P, Tournilhac O, Lepretre S, Aurran T, Villemagne B, Casasnovas O, Nollet D, Dreyfus B, Chevret S, et al. Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase Blood. 134: 346-346. DOI: 10.1182/Blood-2019-122826 |
0.358 |
|
| 2018 |
Heming N, Lamothe L, Jaber S, Trouillet JL, Martin C, Chevret S, Annane D. Morbidity and Mortality of Crystalloids Compared to Colloids in Critically Ill Surgical Patients: A Subgroup Analysis of a Randomized Trial. Anesthesiology. PMID 30212412 DOI: 10.1097/Aln.0000000000002413 |
0.344 |
|
| 2018 |
Roos-Weil D, Nguyen-Khac F, Chevret S, Touzeau C, Roux C, Lejeune J, Cosson A, Mathis S, Feugier P, Leprêtre S, Béné MC, Baron M, Raynaud S, Struski S, Eclache V, et al. Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group. Genes, Chromosomes & Cancer. PMID 30203893 DOI: 10.1002/Gcc.22650 |
0.304 |
|
| 2018 |
Galimard JE, Chevret S, Curis E, Resche-Rigon M. Heckman imputation models for binary or continuous MNAR outcomes and MAR predictors. Bmc Medical Research Methodology. 18: 90. PMID 30170561 DOI: 10.1186/S12874-018-0547-1 |
0.465 |
|
| 2018 |
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica. PMID 30076173 DOI: 10.3324/Haematol.2018.188888 |
0.386 |
|
| 2018 |
Adès L, Thomas X, Guerci Bresler A, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, ... ... Chevret S, et al. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica. PMID 30026341 DOI: 10.3324/Haematol.2018.198614 |
0.341 |
|
| 2018 |
Peffault de Latour R, Chevret S, Jubert C, Sirvent A, Galambrun C, Ruggeri A, Gandemer V, Cornillon J, Rialland F, Dalle JH, Forcade E, Bruno B, Paillard C, Rorlich PS, Salmon A, et al. Unrelated cord blood transplantation in patients with acquired refractory aplastic anemia: a nationwide phase II study. Blood. PMID 29760162 DOI: 10.1182/Blood-2018-01-829630 |
0.355 |
|
| 2018 |
Bergeron A, Chevret S, de Latour RP, Chagnon K, de Margerie-Mellon C, Rivière F, Robin M, Mani J, Lorillon G, Socié G, Tazi A. Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. The European Respiratory Journal. PMID 29650555 DOI: 10.1183/13993003.02617-2017 |
0.37 |
|
| 2018 |
Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, et al. Long-term follow-up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. Haematologica. PMID 29545348 DOI: 10.3324/Haematol.2017.183350 |
0.323 |
|
| 2018 |
Azoulay E, Lemiale V, Mokart D, Nseir S, Argaud L, Pène F, Kontar L, Bruneel F, Klouche K, Barbier F, Reignier J, Stoclin A, Louis G, Constantin JM, Mayaux J, ... ... Chevret S, et al. High-flow nasal oxygen vs. standard oxygen therapy in immunocompromised patients with acute respiratory failure: study protocol for a randomized controlled trial. Trials. 19: 157. PMID 29506579 DOI: 10.1186/S13063-018-2492-Z |
0.313 |
|
| 2018 |
Guen PL, Chevret S, Bugnet E, Margerie-Mellon CD, Jouenne F, Lorillon G, Seguin-Givelet A, Mourah S, Gossot D, Vassallo R, Tazi A. Pneumothorax in pulmonary langerhans cell histiocytosis (PLCH) European Respiratory Journal. 52. DOI: 10.1183/13993003.Congress-2018.Pa2241 |
0.305 |
|
| 2018 |
Ades L, Guerci A, Laribi K, Peterlin P, Vey N, Thepot S, Wickenhauser S, Zerazhi H, Stamatoullas A, Wattel E, Recher C, Toma A, Bouabdallah K, Braun T, Beyne-Rauzy O, ... ... Chevret S, et al. A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial Blood. 132: 467-467. DOI: 10.1182/Blood-2018-99-111756 |
0.347 |
|
| 2018 |
Kiladjian J, Soret-Dulphy J, Resche-Rigon M, Boyer-Perrard F, Barraco F, Rolland-Neyret V, Capron C, Chevret S, Giraudier S, Cassinat B. Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis Blood. 132: 581-581. DOI: 10.1182/Blood-2018-99-110785 |
0.573 |
|
| 2017 |
Grafféo N, Latouche A, Geskus RB, Chevret S. Modeling time-varying exposure using inverse probability of treatment weights. Biometrical Journal. Biometrische Zeitschrift. PMID 29280181 DOI: 10.1002/Bimj.201600223 |
0.615 |
|
| 2017 |
Bridoux F, Carron PL, Pegourie B, Alamartine E, Augeul-Meunier K, Karras A, Joly B, Peraldi MN, Arnulf B, Vigneau C, Lamy T, Wynckel A, Kolb B, Royer B, Rabot N, ... ... Chevret S, et al. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial. Jama. 318: 2099-2110. PMID 29209721 DOI: 10.1001/Jama.2017.17924 |
0.315 |
|
| 2017 |
Lloret-Linares C, Daali Y, Chevret S, Nieto I, Molière F, Courtet P, Galtier F, Richieri RM, Morange S, Llorca PM, El-Hage W, Desmidt T, Haesebaert F, Vignaud P, Holtzmann J, et al. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study). Bmc Pharmacology & Toxicology. 18: 70. PMID 29115994 DOI: 10.1186/S40360-017-0173-2 |
0.306 |
|
| 2017 |
Debourdeau P, Espié M, Chevret S, Gligorov J, Elias A, Dupré PF, Desseaux K, Kalidi I, Villiers S, Giachetti S, Frere C, Farge D. Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. Cancer Medicine. PMID 28980454 DOI: 10.1002/Cam4.1201 |
0.356 |
|
| 2017 |
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, et al. STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network. The Journal of Investigative Dermatology. PMID 28843487 DOI: 10.1016/J.Jid.2017.07.839 |
0.312 |
|
| 2017 |
Biau DJ, Boulezaz S, Casabianca L, Hamadouche M, Anract P, Chevret S. Using Bayesian statistics to estimate the likelihood a new trial will demonstrate the efficacy of a new treatment. Bmc Medical Research Methodology. 17: 128. PMID 28830464 DOI: 10.1186/S12874-017-0401-X |
0.31 |
|
| 2017 |
Flicoteaux R, Protopopescu C, Tibi A, Blanchon T, Werf SV, Duval X, Mosnier A, Charlois-Ou C, Lina B, Leport C, Chevret S. Factors associated with non-persistence to oral and inhaled antiviral therapies for seasonal influenza: a secondary analysis of a double-blind, multicentre, randomised clinical trial. Bmj Open. 7: e014546. PMID 28698321 DOI: 10.1136/Bmjopen-2016-014546 |
0.301 |
|
| 2017 |
Tazi A, Lorillon G, Haroche J, Neel A, Dominique S, Aouba A, Bouaziz JD, de Margerie-Melon C, Bugnet E, Cottin V, Comont T, Lavigne C, Kahn JE, Donadieu J, Chevret S. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet Journal of Rare Diseases. 12: 95. PMID 28532436 DOI: 10.1186/S13023-017-0651-Z |
0.334 |
|
| 2017 |
Leblond V, Morel P, Dilhuidy MS, Leleu X, Soussain C, Leprête S, Dreyfus B, Dartigeas C, Mahé B, Anglaret B, Pégourié B, Besson C, Aurran T, Vekhoff A, Tournilhac O, ... ... Chevret S, et al. A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone. Leukemia & Lymphoma. 1-9. PMID 28395585 DOI: 10.1080/10428194.2017.1307357 |
0.37 |
|
| 2017 |
Robin M, Zine M, Chevret S, Meignin V, Munoz-Bongrand N, Moatti H, Xhaard A, Sicre de Fontbrune F, Peffault de Latour R, Sarfati E, Socié G. The Impact of Splenectomy in Myelofibrosis Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28263921 DOI: 10.1016/J.Bbmt.2017.03.002 |
0.306 |
|
| 2017 |
Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, et al. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016704551. PMID 28221862 DOI: 10.1200/Jco.2016.70.4551 |
0.37 |
|
| 2017 |
Kamilia C, Regaieg K, Baccouch N, Chelly H, Bahloul M, Bouaziz M, Jendoubi A, Abbes A, Belhaouane H, Nasri O, Jenzri L, Ghedira S, Houissa M, Belkadi K, Harti Y, ... ... Chevret S, et al. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress. Annals of Intensive Care. 7: 105-207. PMID 28074416 DOI: 10.1186/S13613-016-0224-7 |
0.481 |
|
| 2016 |
Orlikowski D, Prigent H, Quera Salva MA, Heming N, Chaffaut C, Chevret S, Annane D, Lofaso F, Ogna A. Prognostic value of nocturnal hypoventilation in neuromuscular patients. Neuromuscular Disorders : Nmd. PMID 28153460 DOI: 10.1016/J.Nmd.2016.12.006 |
0.353 |
|
| 2016 |
Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, ... ... Chevret S, et al. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies. Haematologica. PMID 28034993 DOI: 10.3324/Haematol.2016.151894 |
0.365 |
|
| 2016 |
Lemiale V, Resche-Rigon M, Mokart D, Pène F, Argaud L, Mayaux J, Guitton C, Rabbat A, Girault C, Kouatchet A, Vincent F, Bruneel F, Nyunga M, Seguin A, Klouche K, ... ... Chevret S, et al. High-Flow Nasal Cannula Oxygenation in Immunocompromised Patients With Acute Hypoxemic Respiratory Failure: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study. Critical Care Medicine. PMID 27655324 DOI: 10.1097/Ccm.0000000000002085 |
0.533 |
|
| 2016 |
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. The New England Journal of Medicine. 375: 1044-1053. PMID 27626518 DOI: 10.1056/Nejmoa1605085 |
0.353 |
|
| 2016 |
Bernaudin F, Verlhac S, Chevret S. Treating sickle cell anaemia: the TWiTCH trial. Lancet (London, England). 388: 960. PMID 27598674 DOI: 10.1016/S0140-6736(16)31492-1 |
0.365 |
|
| 2016 |
Jaillette E, Girault C, Brunin G, Zerimech F, Chiche A, Broucqsault-Dedrie C, Fayolle C, Minacori F, Alves I, Barrailler S, Robriquet L, Delaporte E, Thellier D, Delcourte C, Duhamel A, ... ... Chevret S, et al. French Intensive Care Society, International congress - Réanimation 2016. Annals of Intensive Care. 6: 50. PMID 27316915 DOI: 10.1186/S13613-016-0114-Z |
0.477 |
|
| 2016 |
Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, et al. A randomised phase II trial of azacitidine +/- epoetin beta In lower risk myelodysplastic syndromes if resistant to erythropoietic stimulating agents. Haematologica. PMID 27229713 DOI: 10.3324/Haematol.2015.140988 |
0.327 |
|
| 2016 |
Biard L, Labopin M, Chevret S, Resche-Rigon M. Investigating covariate-by-centre interaction in survival data. Statistical Methods in Medical Research. 27: 920-932. PMID 27166409 DOI: 10.1177/0962280216647981 |
0.563 |
|
| 2016 |
Galimard JE, Chevret S, Protopopescu C, Resche-Rigon M. A multiple imputation approach for MNAR mechanisms compatible with Heckman's model. Statistics in Medicine. 35: 2907-20. PMID 26893215 DOI: 10.1002/sim.6902 |
0.476 |
|
| 2016 |
Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 30: 897-905. PMID 26500139 DOI: 10.1038/Leu.2015.296 |
0.328 |
|
| 2016 |
Lambert J, Chevret S. Summary measure of discrimination in survival models based on cumulative/dynamic time-dependent ROC curves. Statistical Methods in Medical Research. 25: 2088-2102. PMID 24395866 DOI: 10.1177/0962280213515571 |
0.334 |
|
| 2016 |
Moatti M, Chevret S, Zohar S, Rosenberger WF. A Bayesian hybrid adaptive randomisation design for clinical trials with survival outcomes Methods of Information in Medicine. 55: 4-13. DOI: 10.3414/Me14-01-0132 |
0.626 |
|
| 2016 |
Ogna A, Prigent H, Salva MQ, Chevret S, Heming N, Annane D, Lofaso F, Orlikowski D. Prognostic value of nocturnal hypoventilation in unventilated neuromuscular disease patients European Respiratory Journal. 48. DOI: 10.1183/13993003.Congress-2016.Pa2170 |
0.358 |
|
| 2016 |
Bridoux F, Pegourie B, Augeul-Meunier K, Royer B, Joly B, Lamy T, Kolb B, Benboubker L, Arnulf B, Jaccard A, Chevret S, Fermand J. Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT)) Blood. 128: 978-978. DOI: 10.1182/Blood.V128.22.978.978 |
0.345 |
|
| 2016 |
Ades L, Thomas X, Guerci A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Bron D, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P. Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial) Blood. 128: 898-898. DOI: 10.1182/Blood.V128.22.898.898 |
0.336 |
|
| 2016 |
Peffault de Latour R, Chevret S, Ruggeri A, Suarez F, Souchet L, Michonneau D, Sicre de Fontbrune F, Coman T, Rubio Mt, Nguyen S, Mohty M, Socie G. Romiplostim in Patients Undergoing Allogeneic Stem Cell Transplantation: Results of a Phase I/II Multicenter Trial Blood. 128: 65-65. DOI: 10.1182/Blood.V128.22.65.65 |
0.323 |
|
| 2016 |
Mansour S, Jacob L, Amorim S, Potier J, Brice P, Vercellino L, Kerviler Ed, Meignin V, Chevret S, Thieblemont C. Tolerance and Efficacy of L-Asparaginase during Induction of Extra-Nodal Natural Killer (NK/T) Lymphoma, Nasal Type, in Real-Life Experience Blood. 128: 5351-5351. DOI: 10.1182/Blood.V128.22.5351.5351 |
0.348 |
|
| 2016 |
Bergeron A, Chevret S, Peffault De La Tour R, Chagnon K, De Bazelaire C, Rivière F, Robin M, Mani J, Lorillon G, Gérard S, Tazi A. Incidence, Risk Factors and Outcome of Late Onset Noninfectious Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Cohort Study Blood. 128: 4562-4562. DOI: 10.1182/Blood.V128.22.4562.4562 |
0.38 |
|
| 2016 |
Sebert M, Bally C, Peterlin P, Beyne-Rauzy O, Legros L, Gourin mP, Sanhes L, Wattel E, Gyan E, Park S, Stamatoullas A, Banos A, Laribi K, Jueliger S, Bevan L, ... ... Chevret S, et al. Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment Blood. 128: 347-347. DOI: 10.1182/Blood.V128.22.347.347 |
0.334 |
|
| 2016 |
Dupriez B, Chevret S, Ianotto J, Boyer F, Cony-Makhoul P, Etienne G, Wemeau M, Rey J, Knoops L, Demory J, Lippert E, Girodon F, Legros L, Vekhoff A, Courby S, et al. Myelofibrosis in Real Life: Findings from the French Intergroup of Myeloproliferative Neoplasms (FIM) Registry Blood. 128: 3128-3128. DOI: 10.1182/Blood.V128.22.3128.3128 |
0.318 |
|
| 2016 |
Soret J, Cassinat B, Chevret S, Dosquet C, Giraudier S, Verger E, Maslah N, Parquet N, Chomienne C, Kiladjian J. Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation Blood. 128: 3106-3106. DOI: 10.1182/Blood.V128.22.3106.3106 |
0.319 |
|
| 2016 |
Peffault de Latour R, Chevret S, Jubert C, Sirvent A, Galambrun C, Ruggeri A, Gandemer V, Cornillon J, Rialland F, Dalle J, Milpied N, Bruno B, Paillard C, Legrand F, Salmon A, et al. Efficacy and Safety of Unrelated Cord Blood Transplantation in Patients with Acquired Refractory Aplastic Anemia: A Phase II Study on Behalf of Eurocord and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy Blood. 128: 2671-2671. DOI: 10.1182/Blood.V128.22.2671.2671 |
0.321 |
|
| 2016 |
Debourdeau P, Espié M, Chevret S, Gligorov J, Elias A, Dupré PF, Le Long J, Lavau-Denes S, Sevestre M, Bastit L, Kalidi I, Frere C, Farge D. Incidence and Risk Factors for Central Venous Catheter-Related Venous Thromboembolism in Breast Cancer Patients Under Neoadjuvant Chemotherapy: the Caveccas (Catheter Veineux Central et Cancer du Sein) Study Blood. 128: 2607-2607. DOI: 10.1182/Blood.V128.22.2607.2607 |
0.329 |
|
| 2016 |
Pagliuca S, Risitano AM, Chevret S, Sicre de Fontbrune F, Xhaard A, Coman T, Michonneau D, Marotta S, Ruggiu M, Bredin S, Peffault de Latour R, Socié G, Robin M. Evaluation of Graft Versus Host Disease and Relapse Free Survival As Novel Endpoint in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Joint Naples-Paris Study Blood. 128: 2285-2285. DOI: 10.1182/Blood.V128.22.2285.2285 |
0.34 |
|
| 2016 |
Petit A, Trinquand A, Chevret S, Ballerini PF, Cayuela J, Grardel N, Touzart A, Brethon B, Lapillonne H, Chastagner P, Berger C, Michel G, Preudhomme C, Soulier J, Landman-Parker J, et al. Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines Blood. 128: 1083-1083. DOI: 10.1182/Blood.V128.22.1083.1083 |
0.322 |
|
| 2015 |
Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26681685 DOI: 10.1093/Annonc/Mdv616 |
0.311 |
|
| 2015 |
Lemiale V, Mokart D, Resche-Rigon M, Pène F, Mayaux J, Faucher E, Nyunga M, Girault C, Perez P, Guitton C, Ekpe K, Kouatchet A, Théodose I, Benoit D, Canet E, ... ... Chevret S, et al. Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure: A Randomized Clinical Trial. Jama. 314: 1711-9. PMID 26444879 DOI: 10.1001/Jama.2015.12402 |
0.504 |
|
| 2015 |
Lemiale V, Resche-Rigon M, Mokart D, Pène F, Rabbat A, Kouatchet A, Vincent F, Bruneel F, Nyunga M, Lebert C, Perez P, Meert AP, Benoit D, Chevret S, Azoulay E. Acute respiratory failure in patients with hematological malignancies: outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en réanimation onco-hématologique (Grrr-OH) study. Annals of Intensive Care. 5: 28. PMID 26429355 DOI: 10.1186/S13613-015-0070-Z |
0.558 |
|
| 2015 |
Caruana E, Chevret S, Resche-Rigon M, Pirracchio R. A new weighted balance measure helped to select the variables to be included in a propensity score model. Journal of Clinical Epidemiology. 68: 1415-22.e2. PMID 26050059 DOI: 10.1016/J.Jclinepi.2015.04.009 |
0.516 |
|
| 2015 |
Feghoul L, Chevret S, Cuinet A, Dalle JH, Ouachée M, Yacouben K, Fahd M, Guérin-El Khourouj V, Roupret-Serzec J, Sterkers G, Baruchel A, Simon F, LeGoff J. Adenovirus infection and disease in paediatric haematopoietic stem cell transplant patients: clues for antiviral pre-emptive treatment. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 21: 701-9. PMID 25882354 DOI: 10.1016/J.Cmi.2015.03.011 |
0.305 |
|
| 2015 |
Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, ... ... Chevret S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 125: 3711-9. PMID 25878120 DOI: 10.1182/Blood-2015-02-627935 |
0.352 |
|
| 2015 |
Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, et al. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. Cancer. 121: 2393-9. PMID 25845577 DOI: 10.1002/Cncr.29389 |
0.33 |
|
| 2015 |
Kentish-Barnes N, Chaize M, Seegers V, Legriel S, Cariou A, Jaber S, Lefrant JY, Floccard B, Renault A, Vinatier I, Mathonnet A, Reuter D, Guisset O, Cohen-Solal Z, Cracco C, ... ... Chevret S, et al. Complicated grief after death of a relative in the intensive care unit. The European Respiratory Journal. 45: 1341-52. PMID 25614168 DOI: 10.1183/09031936.00160014 |
0.306 |
|
| 2015 |
Chevret S, Seaman S, Resche-Rigon M. Multiple imputation: a mature approach to dealing with missing data. Intensive Care Medicine. 41: 348-50. PMID 25578679 DOI: 10.1007/S00134-014-3624-X |
0.559 |
|
| 2015 |
Mokart D, Darmon M, Resche-Rigon M, Lemiale V, Pène F, Mayaux J, Rabbat A, Kouatchet A, Vincent F, Nyunga M, Bruneel F, Lebert C, Perez P, Renault A, Hamidfar R, ... ... Chevret S, et al. Prognosis of neutropenic patients admitted to the intensive care unit. Intensive Care Medicine. 41: 296-303. PMID 25578678 DOI: 10.1007/S00134-014-3615-Y |
0.495 |
|
| 2015 |
Rio B, Chevret S, Vigouroux S, Chevallier P, Fürst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Françoise S, Legrand F, Yakoub-Agha I, Michel G, et al. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 445-53. PMID 25460357 DOI: 10.1016/J.Bbmt.2014.11.009 |
0.352 |
|
| 2015 |
Pouessel D, Chevret S, Roubaud G, Aarab-Terrisse S, Chevreau C, Vordos D, Rolland F, Boudin L, Joly F, Joly C, Beuzeboc P, Boyle HJ, Farneti D, Dauba J, Moriceau G, et al. A comparison of the outcomes after neoadjuvant (NC) or adjuvant chemotherapy (AC) for muscle-invasive urothelial bladder cancer (UC): A French contemporary retrospective multicenter cohort. Journal of Clinical Oncology. 33: 325-325. DOI: 10.1200/Jco.2015.33.7_Suppl.325 |
0.312 |
|
| 2015 |
Hurabielle C, Pillebout E, Stehle T, Pagès C, Roux J, Schneider P, Chevret S, Mourah S, Basset-Seguin N, Chaffaut C, Vidal-Petiot E, Flamant M, Lebbe C. Mechanisms of elevated serum creatinine in patients receiving vemurafenib for advanced melanoma. Journal of Clinical Oncology. 33: e20022-e20022. DOI: 10.1200/Jco.2015.33.15_Suppl.E20022 |
0.314 |
|
| 2015 |
Ogna A, Nardi J, Prigent H, Salva MQ, Chevret S, Annane D, Orlikowski D, Lofaso F. Prognostic value of residual hypoventilation in mechanically ventilated neuromuscular patients: A 5 years follow-up study European Respiratory Journal. 46. DOI: 10.1183/13993003.Congress-2015.Oa4781 |
0.36 |
|
| 2015 |
Bernaudin F, Verlhac S, Ducros-Miralles E, Delatour RP, Dalle J, Petras E, Brousse V, Thuret I, Paillard C, Neven B, Galambrun C, Etienne-Julian M, Pondarre C, Lutz L, Guitton C, ... ... Chevret S, et al. French National Drepagreffe Trial: Cognitive Performances and Neuroimaging at Enrollment and after 12 Months on Transfusion Program or Transplantation (AP-HP: NCT 01340404) Blood. 126: 544-544. DOI: 10.1182/Blood.V126.23.544.544 |
0.316 |
|
| 2015 |
Ades L, Thomas X, Guerci-Bresler A, Emmanuel R, Spertini O, Vey N, Lamy T, Récher C, Pigneux A, Bordessoule D, Deconinck E, Gardin C, Tournilhac O, Lambert J, Chevallier P, ... ... Chevret S, et al. Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group Blood. 126: 451-451. DOI: 10.1182/Blood.V126.23.451.451 |
0.318 |
|
| 2015 |
Amah S, Poirot C, Chevret S, Fahd M, Yakouben K, Ouachee M, Carel JC, Baruchel A, Dalle J. Acceptability of the Fertility Preservation Program and Evaluation of the Gonadal Function in Children after Allogeneic Stem Cell Transplantation Blood. 126: 4357-4357. DOI: 10.1182/Blood.V126.23.4357.4357 |
0.321 |
|
| 2015 |
Prebet T, Delaunay J, Wattel E, Braun T, Cony-Makhoul P, Dimicoli S, Wickenhauser S, Lejeune J, Chevret S, Chermat F, Fenaux P, Vey N. A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study Blood. 126: 2900-2900. DOI: 10.1182/Blood.V126.23.2900.2900 |
0.38 |
|
| 2015 |
Sebert M, Stamatoullas A, Braun T, Delaunay J, de Renzis B, Jeddi R, Meddeb B, Hunault Berger M, Samey B, Chermat F, Chevret S, Chaffaut C, Fenaux P, Ades L. Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM) Blood. 126: 2884-2884. DOI: 10.1182/Blood.V126.23.2884.2884 |
0.358 |
|
| 2015 |
Ades L, Guerci-Bresler A, Cony-Makhoul P, Legros L, Sebert M, Braun T, Delaunay J, Samey B, Desseaux K, Chevret S, Fenaux P. A Phase II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (AZA) in Intermediate-2 and High Risk MDS Patients: A Study By the Groupe Francophone Des Myelodysplasies (GFM) Blood. 126: 2869-2869. DOI: 10.1182/Blood.V126.23.2869.2869 |
0.344 |
|
| 2015 |
Thomas X, De Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau J, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn J, Hermine O, et al. Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412) Blood. 126: 218-218. DOI: 10.1182/Blood.V126.23.218.218 |
0.387 |
|
| 2015 |
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Braun T, Marolleau J, Chalandon Y, et al. Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study Blood. 126: 1-1. DOI: 10.1182/Blood.V126.23.1.1 |
0.37 |
|
| 2014 |
Pibouleau L, Chevret S. An internet-based method to elicit experts' beliefs for Bayesian priors: a case study in intracranial stent evaluation. International Journal of Technology Assessment in Health Care. 30: 446-53. PMID 25401304 DOI: 10.1017/S0266462314000403 |
0.763 |
|
| 2014 |
Lapidus N, Chevret S, Resche-Rigon M. Assessing assay agreement estimation for multiple left-censored data: a multiple imputation approach. Statistics in Medicine. 33: 5298-309. PMID 25292387 DOI: 10.1002/Sim.6319 |
0.508 |
|
| 2014 |
Lambert J, Lambert J, Nibourel O, Pautas C, Hayette S, Cayuela JM, Terré C, Rousselot P, Dombret H, Chevret S, Preudhomme C, Castaigne S, Renneville A. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget. 5: 6280-8. PMID 25026287 DOI: 10.18632/Oncotarget.2196 |
0.361 |
|
| 2014 |
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials The Lancet Oncology. 15: 986-996. PMID 25008258 DOI: 10.1016/S1470-2045(14)70281-5 |
0.353 |
|
| 2014 |
Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, Thomas X, Cayuela JM, Grardel N, Chalandon Y, Boissel N, Schaefer B, Delabesse E, Cavé H, Chevallier P, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 123: 3739-49. PMID 24740809 DOI: 10.1182/Blood-2014-01-547695 |
0.317 |
|
| 2014 |
Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, et al. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. Oncotarget. 5: 916-32. PMID 24659740 DOI: 10.18632/Oncotarget.1536 |
0.335 |
|
| 2014 |
Sarkozy C, Terré C, Jardin F, Radford I, Roche-Lestienne C, Penther D, Bastard C, Rigaudeau S, Pilorge S, Morschhauser F, Bouscary D, Delarue R, Farhat H, Rousselot P, Hermine O, ... ... Chevret S, et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes, Chromosomes & Cancer. 53: 106-16. PMID 24249260 DOI: 10.1002/Gcc.22123 |
0.347 |
|
| 2014 |
Debourdeau P, Espie M, Gligorov J, Elias A, Sevestre MA, Dupre P, LeLong J, Lavau-Denes S, Bastit L, Kalidi I, Chevret S, Farge D. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: Results of the CAVECCAS study. Journal of Clinical Oncology. 32: e20616-e20616. DOI: 10.1200/Jco.2014.32.15_Suppl.E20616 |
0.312 |
|
| 2014 |
Fleury I, Chevret S, Amorim S, Zucca E, Herold M, Ghielmini M, Brice P, Coiffier B, Salles GA, Thieblemont C. Meta-analysis of the risk of secondary neoplasm in patients treated for non-Hodgkin lymphoma with rituximab. Journal of Clinical Oncology. 32: e19541-e19541. DOI: 10.1200/Jco.2014.32.15_Suppl.E19541 |
0.345 |
|
| 2014 |
Lebbe C, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault J, Avril M, Bedane C, Bens G, Beylot-Barry M, Mansard S, Grange F, Meyer N, Machet L, et al. Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification. Journal of Clinical Oncology. 32: 9032-9032. DOI: 10.1200/Jco.2014.32.15_Suppl.9032 |
0.332 |
|
| 2014 |
Pouessel D, Chevret S, Bompas E, Boudin L, Joly C, Grellety T, Aarab Terrisse S, Boyle HJ, Roubaud G, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, et al. Pathologic down-staging following standard (SD) MVAC (methotrexate-vinblastine-doxorubicine-cisplatin) or dose-dense MVAC (DD) neoadjuvant chemotherapy (NC) for muscle-invasive urothelial bladder cancer (UC): A retrospective multicenter cohort of the French Genitourinary Tumor Group (GETUG/AFU). Journal of Clinical Oncology. 32: 4550-4550. DOI: 10.1200/Jco.2014.32.15_Suppl.4550 |
0.303 |
|
| 2014 |
Castaigne S, Pautas C, Terré C, Renneville A, Gardin C, Suarez F, Caillot D, Berthon C, Rousselot P, Preudhomme C, Morisset L, Celli Lebras K, Chevret S, Dombret H. Final Analysis of the ALFA 0701 Study Blood. 124: 376-376. DOI: 10.1182/Blood.V124.21.376.376 |
0.381 |
|
| 2014 |
Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C. No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials Blood. 124: 1659-1659. DOI: 10.1182/Blood.V124.21.1659.1659 |
0.377 |
|
| 2013 |
Pirracchio R, Resche-Rigon M, Chevret S, Journois D. Do simple screening statistical tools help to detect reporting bias? Annals of Intensive Care. 3: 29. PMID 24004521 DOI: 10.1186/2110-5820-3-29 |
0.524 |
|
| 2013 |
Moatti M, Zohar S, Facon T, Moreau P, Mary JY, Chevret S. Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial. Clinical Trials (London, England). 10: 505-14. PMID 23820061 DOI: 10.1177/1740774513493528 |
0.598 |
|
| 2013 |
Azoulay E, Mokart D, Pène F, Lambert J, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Laisne LM, Rabbat A, Lebert C, Perez P, Chaize M, Renault A, ... ... Chevret S, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2810-8. PMID 23752112 DOI: 10.1200/Jco.2012.47.2365 |
0.375 |
|
| 2013 |
Sarkozy C, Gardin C, Gachard N, Merabet F, Turlure P, Malfuson JV, Pautas C, Micol JB, Thomas X, Quesnel B, Celli-Lebras K, Preudhomme C, Terré C, Fenaux P, Chevret S, et al. Outcome of older patients with acute myeloid leukemia in first relapse. American Journal of Hematology. 88: 758-64. PMID 23749683 DOI: 10.1002/Ajh.23498 |
0.365 |
|
| 2013 |
Pirracchio R, Resche-Rigon M, Chevret S, Journois D. Simple screening statistical tools to detect reporting bias: when should we ask for raw data? Critical Care (London, England). 17: 142. PMID 23659737 DOI: 10.1186/Cc12611 |
0.531 |
|
| 2013 |
Kant A, Gupta PK, Zohar S, Chevret S, Hopkins PM. Application of the continual reassessment method to dose-finding studies in regional anesthesia: an estimate of the ED95 dose for 0.5% bupivacaine for ultrasound-guided supraclavicular block. Anesthesiology. 119: 29-35. PMID 23648519 DOI: 10.1097/Aln.0B013E31829764Cf |
0.582 |
|
| 2013 |
Pibouleau L, Chevret S. Bayesian hierarchical meta-analysis model for medical device evaluation: application to intracranial stents. International Journal of Technology Assessment in Health Care. 29: 123-30. PMID 23601495 DOI: 10.1017/S0266462313000093 |
0.763 |
|
| 2013 |
Adès L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Lambert JF, Lioure B, de Botton S, Deconinck E, Ferrant A, Thomas X, et al. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. American Journal of Hematology. 88: 556-9. PMID 23564205 DOI: 10.1002/Ajh.23451 |
0.359 |
|
| 2013 |
Gupta PK, Chevret S, Zohar S, Hopkins PM. What is the ED95 of prilocaine for femoral nerve block using ultrasound? British Journal of Anaesthesia. 110: 831-6. PMID 23393153 DOI: 10.1093/Bja/Aes503 |
0.534 |
|
| 2013 |
de Montmollin E, Tandjaoui-Lambiotte Y, Legrand M, Lambert J, Mokart D, Kouatchet A, Lemiale V, Pène F, Bruneel F, Vincent F, Mayaux J, Chevret S, Azoulay E. Outcomes in critically ill cancer patients with septic shock of pulmonary origin. Shock (Augusta, Ga.). 39: 250-4. PMID 23364436 DOI: 10.1097/Shk.0B013E3182866D32 |
0.367 |
|
| 2013 |
Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM, Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 121: 2213-23. PMID 23321257 DOI: 10.1182/Blood-2012-10-462879 |
0.337 |
|
| 2013 |
Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S, Gachard N, Renneville A, Boissel N, Preudhomme C, Terré C, Fenaux P, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 321-7. PMID 23248249 DOI: 10.1200/Jco.2011.40.3642 |
0.322 |
|
| 2013 |
Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 301-7. PMID 23233721 DOI: 10.1200/Jco.2012.44.7920 |
0.377 |
|
| 2013 |
Mokart D, Lambert J, Schnell D, Fouché L, Rabbat A, Kouatchet A, Lemiale V, Vincent F, Lengliné E, Bruneel F, Pene F, Chevret S, Azoulay E. Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. Leukemia & Lymphoma. 54: 1724-9. PMID 23185988 DOI: 10.3109/10428194.2012.753446 |
0.328 |
|
| 2013 |
Azoulay E, Kouatchet A, Jaber S, Lambert J, Meziani F, Schmidt M, Schnell D, Mortaza S, Conseil M, Tchenio X, Herbecq P, Andrivet P, Guerot E, Lafabrie A, Perbet S, ... ... Chevret S, et al. Noninvasive mechanical ventilation in patients having declined tracheal intubation. Intensive Care Medicine. 39: 292-301. PMID 23184037 DOI: 10.1007/S00134-012-2746-2 |
0.325 |
|
| 2013 |
Zohar S, Resche-Rigon M, Chevret S. Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. Clinical Trials (London, England). 10: 414-21. PMID 21824977 DOI: 10.1177/1740774511411593 |
0.689 |
|
| 2013 |
Toma A, Chevret S, Kosmider O, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guercy-Bresler A, Jourdan E, Sardnal V, Caillot D, Laribi K, De Renzis B, Bordessoule D, et al. A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO. Journal of Clinical Oncology. 31: 7002-7002. DOI: 10.1200/Jco.2013.31.15_Suppl.7002 |
0.317 |
|
| 2013 |
Thepot S, Abdelali RB, Chevret S, Renneville A, Rauzy OB, Prebet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastie J, Delaunay J, et al. Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM Blood. 122: 658-658. DOI: 10.1182/Blood.V122.21.658.658 |
0.349 |
|
| 2013 |
Ades L, Chevret S, Raffoux E, Pigneux A, Thomas X, Bordessoule D, Vey N, Guerci-Bresler A, Lamy T, Recher C, Lambert J, Tournilhac O, Pautas C, Carre M, Bron D, et al. Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL– Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group Blood. 122: 495-495. DOI: 10.1182/Blood.V122.21.495.495 |
0.326 |
|
| 2013 |
Lengliné E, Moreau a, Chevret S, Pene F, Blot F, Bourhis J, Buzyn A, Schlemmer B, Socié G, Azoulay E. Intensive Care Management and Outcomes In Allogeneic Hematopoietic Stem Cell Transplantation Recipients Blood. 122: 4560-4560. DOI: 10.1182/Blood.V122.21.4560.4560 |
0.36 |
|
| 2013 |
Leblond V, Chevret S, Dilhuydy mS, Leleu X, Soussain C, Leprêtre S, Dreyfus B, Dartigeas C, Mahe B, Anglaret B, Pegourie B, Besson C, Aurran T, Vekhoff A, Tournilhac O, et al. Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738) Blood. 122: 4359-4359. DOI: 10.1182/Blood.V122.21.4359.4359 |
0.344 |
|
| 2013 |
Roos-Weil D, Nguyen-Khac F, Chevret S, Roux C, Touzeau C, Cosson A, Cymbalista F, Feugier P, Leprêtre S, Bene M, Raynaud S, Sutton L, Davi F, Leblond V. Mutational and Cytogenetic Analyses Of 177 CLL Patients With Trisomy 12: A Retrospective Study Of The CLL French Intergroup Blood. 122: 4144-4144. DOI: 10.1182/Blood.V122.21.4144.4144 |
0.338 |
|
| 2013 |
Hills RK, Petersdorf S, Estey EH, Othus M, Appelbaum FR, Castaigne S, Dombret H, Chevret S, Delaunay J, Ifrah N, Cahn J, Recher C, Burnett AK. The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials Blood. 122: 356-356. DOI: 10.1182/Blood.V122.21.356.356 |
0.407 |
|
| 2013 |
Feugier P, Letestu R, Chevret S, Aurran T, Mahe B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Delepine R, Vaudaux S, et al. Updated Follow-Up In The CLL2007FMP Trial Supports The Non Superiority Of The Association Fludarabine-Cyclophosphamide (FC) Plus Campath Compared To FC Plus Rituximab and Points Out The Importance Of Minimal Residual Disease, By 6-Color Flow Cytometry Technique, On Progression Free Survival Blood. 122: 2870-2870. DOI: 10.1182/Blood.V122.21.2870.2870 |
0.407 |
|
| 2013 |
Ades L, Recher C, Stamatoullas A, Bouabdallah K, Delaunay J, Dreyfus F, Vey N, de Renzis B, Raffoux E, Isnard F, Samey B, Chaffaut C, Chevret S, Fenaux P. A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q – A Study By The Groupe Francophone Des Myelodysplasies (GFM) Blood. 122: 2750-2750. DOI: 10.1182/Blood.V122.21.2750.2750 |
0.367 |
|
| 2013 |
Mamez A, Raffoux E, Chevret S, Lemiale V, Boissel N, Canet E, Schlemmer B, Dombret H, Azoulay E, Lengliné E. Oral Hydroxyurea Before Intensive Chemotherapy For Hyperleucocytic Acute Myeloid Leukemia Patients Blood. 122: 2657-2657. DOI: 10.1182/Blood.V122.21.2657.2657 |
0.395 |
|
| 2013 |
Ades L, Guerci-Bresler A, Makhoul PC, Legros L, Delaunay J, Recher C, Desseaux K, Samey B, Chevret S, Fenaux P. A Phase II Study Of The Efficacy and Safety Of An Intensified Schedule Of Azacitidine (AZA) In Intermediate-2 and High Risk MDS Patients Blood. 122: 1513-1513. DOI: 10.1182/Blood.V122.21.1513.1513 |
0.337 |
|
| 2012 |
Trioche P, Nelken B, Michel G, Pellier I, Petit A, Bertrand Y, Rohrlich P, Schmitt C, Sirvent N, Boutard P, Margueritte G, Pautard B, Ducassou S, Plantaz D, Robert A, ... ... Chevret S, et al. French "real life" experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia. Experimental Hematology & Oncology. 1: 39. PMID 23227903 DOI: 10.1186/2162-3619-1-39 |
0.388 |
|
| 2012 |
Resche-Rigon M, Pirracchio R, Robin M, De Latour RP, Sibon D, Ades L, Ribaud P, Fermand JP, Thieblemont C, Socié G, Chevret S. Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases. Bmc Blood Disorders. 12: 10. PMID 22898556 DOI: 10.1186/1471-2326-12-10 |
0.548 |
|
| 2012 |
Pirracchio R, Resche-Rigon M, Chevret S. Evaluation of the propensity score methods for estimating marginal odds ratios in case of small sample size. Bmc Medical Research Methodology. 12: 70. PMID 22646911 DOI: 10.1186/1471-2288-12-70 |
0.508 |
|
| 2012 |
Gandemer V, Chevret S, Petit A, Vermylen C, Leblanc T, Michel G, Schmitt C, Lejars O, Schneider P, Demeocq F, Bader-Meunier B, Bernaudin F, Perel Y, Auclerc MF, Cayuela JM, et al. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol. Haematologica. 97: 1743-50. PMID 22580999 DOI: 10.3324/Haematol.2011.059584 |
0.333 |
|
| 2012 |
Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, ... ... Chevret S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 379: 1508-16. PMID 22482940 DOI: 10.1016/S0140-6736(12)60485-1 |
0.366 |
|
| 2012 |
Lepretre S, Aurran T, Mahé B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van Den Neste E, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 119: 5104-10. PMID 22337714 DOI: 10.1182/Blood-2011-07-365437 |
0.37 |
|
| 2012 |
Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 119: 2228-33. PMID 22223822 DOI: 10.1182/Blood-2011-08-376012 |
0.315 |
|
| 2012 |
Farhat H, Reman O, Raffoux E, Berthon C, Pautas C, Kammoun L, Chantepie S, Gardin C, Rousselot P, Chevret S, Dombret H, Castaigne S. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association. American Journal of Hematology. 87: 62-5. PMID 22072535 DOI: 10.1002/Ajh.22201 |
0.312 |
|
| 2012 |
Pichereau C, Desseaux K, Janin A, Scieux C, Peffault de Latour R, Xhaard A, Robin M, Ribaud P, Agbalika F, Chevret S, Socié G. The complex relationship between human herpesvirus 6 and acute graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 141-4. PMID 21801705 DOI: 10.1016/J.Bbmt.2011.07.018 |
0.321 |
|
| 2012 |
Rahmé R, Thomas X, Recher C, Vey N, Delaunay J, Deconinck E, Bordessoule D, Micol J, Stamatoullas A, Mariette C, Pautas C, Bories P, Marolleau J, Hunault-Berger M, Fegueux N, ... ... Chevret S, et al. Early Deaths (ED) in Acute Promyelocytic Leukemia (APL) in France: A Retrospective Multicenter Study in 355 Patients (pts) Blood. 120: 890-890. DOI: 10.1182/Blood.V120.21.890.890 |
0.315 |
|
| 2012 |
Harel S, Bernard S, Chevret S, Latour RPd, Karlin L, Robin M, Ades L, Szalat R, Malphette M, Asli B, Fermand JP, Arnulf B, Socie G. Impact of Tandem Autologous/Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose Therapy in the Era of Novels Anti-Myeloma Agents Blood. 120: 2035-2035. DOI: 10.1182/Blood.V120.21.2035.2035 |
0.374 |
|
| 2012 |
Chalandon Y, Thomas X, Hayette S, Cayuela J, Abbal C, Huguet F, Raffoux E, Leguay T, Leprêtre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert J, Lafage M, ... ... Chevret S, et al. Is Less Chemotherapy Detrimental in Adults with Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with High-Dose Imatinib? Results of the Prospective Randomized Graaph-2005 Study Blood. 120: 138-138. DOI: 10.1182/Blood.V120.21.138.138 |
0.366 |
|
| 2011 |
Pirracchio R, Sprung C, Payen D, Chevret S. Benefits of ICU admission in critically ill patients: whether instrumental variable methods or propensity scores should be used. Bmc Medical Research Methodology. 11: 132. PMID 21936926 DOI: 10.1186/1471-2288-11-132 |
0.332 |
|
| 2011 |
Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3907-13. PMID 21911721 DOI: 10.1200/Jco.2011.36.0792 |
0.355 |
|
| 2011 |
Pirracchio R, Sprung CL, Payen D, Chevret S. Utility of time-dependent inverse-probability-of-treatment weights to analyze observational cohorts in the intensive care unit. Journal of Clinical Epidemiology. 64: 1373-82. PMID 21652175 DOI: 10.1016/J.Jclinepi.2011.02.009 |
0.311 |
|
| 2011 |
Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, George SL, Bloomfield CD, Castaigne S, Chevret S, Blaise D, Maraninchi D, Lucchesi KJ, Burzykowski T. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. 117: 7007-13. PMID 21518931 DOI: 10.1182/Blood-2011-02-337725 |
0.325 |
|
| 2011 |
Sutton L, Chevret S, Tournilhac O, Diviné M, Leblond V, Corront B, Leprêtre S, Eghbali H, Van Den Neste E, Michallet M, Maloisel F, Bouabdallah K, Decaudin D, Berthou C, Brice P, et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 117: 6109-19. PMID 21406717 DOI: 10.1182/Blood-2010-11-317073 |
0.38 |
|
| 2011 |
Seegers V, Chevret S, Resche-Rigon M. Dose-finding design driven by efficacy in onco-hematology phase I/II trials. Statistics in Medicine. 30: 1574-83. PMID 21394754 DOI: 10.1002/Sim.4152 |
0.56 |
|
| 2011 |
Pibouleau L, Chevret S. Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices. Journal of Clinical Epidemiology. 64: 270-9. PMID 20800443 DOI: 10.1016/J.Jclinepi.2010.03.018 |
0.757 |
|
| 2011 |
Leblond V, Lejeune J, Tournilhac O, Morel P, Dilhuydy mS, Dartigeas C, Malphette M, Royer B, Seymour JF, Chevret S, Johnson S, Owen RG. International Phase III Study of Chlorambucil Versus Fludarabine As Initial Therapy for Waldenstrom's Macroglobulinemia and Related Disorders: Results in 414 Patients on Behalf of FCG CLL/ WM, GOELAMS, GELA, NCRI, ALLG Blood. 118: 776-776. DOI: 10.1182/Blood.V118.21.776.776 |
0.342 |
|
| 2011 |
Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie J, Legrand O, Thomas X, Turlure P, Reman O, De Revel T, Gastaud L, Gardin C, Sutton L, Marolleau JP, ... ... Chevret S, et al. Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA) Blood. 118: 6-6. DOI: 10.1182/Blood.V118.21.6.6 |
0.345 |
|
| 2011 |
Beldjord K, Macintyre E, Lhéritier V, Boulland M, Leguay T, Thomas X, Cayuela J, Grardel N, Chalandon Y, Boissel N, Schäfer B, Cavé H, Chevallier P, Buzyn A, Fest T, ... ... Chevret S, et al. Minimal Residual Disease At 3 Months, Combined to the Presence of IKZF1 Deletion in B-Lineage or Absence of NOTCH1 pathway Mutation in T-Lineage, Recapitulates the Disease Risk Assessment in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia - A GRAALL Study Blood. 118: 572-572. DOI: 10.1182/Blood.V118.21.572.572 |
0.371 |
|
| 2011 |
Sarkozy C, Gardin C, Gachard N, Merabet F, Turlure P, Malfuson J, Pautas C, Micol J, Thomas X, Quesnel B, Celli-Lebras K, Preudhomme C, Terré C, Chevret S, Michallet M, et al. Older Patients with Acute Myeloid Leukemia (AML) in First Relapse: Impact of Genetics and of Salvage Therapy. A Study of the Acute Leukemia French Association (ALFA) Blood. 118: 253-253. DOI: 10.1182/Blood.V118.21.253.253 |
0.372 |
|
| 2011 |
Gandemer V, Chevret S, Petit A, Vermylen C, Leblanc T, Michel G, Schmitt C, Lejars O, Vannier J, Demeocq F, Bader-Meunier B, Bernaudin F, Perel Y, Auclerc M, Cayuela JM, et al. Excellent Prognosis of Late Relapses of ETV6/RUNX1 Childhood Acute Lymphoblastic Leukemia: Lessons From the FRALLE 93 Protocol Blood. 118: 1508-1508. DOI: 10.1182/Blood.V118.21.1508.1508 |
0.354 |
|
| 2011 |
Annane D, Chevret S, Raphael JC. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials: reply to comment by Birmingham and Hoffman Intensive Care Medicine. 37: 1219-1219. DOI: 10.1007/S00134-011-2201-9 |
0.329 |
|
| 2010 |
Raffoux E, Cras A, Recher C, Boëlle PY, de Labarthe A, Turlure P, Marolleau JP, Reman O, Gardin C, Victor M, Maury S, Rousselot P, Malfuson JV, Maarek O, Daniel MT, ... ... Chevret S, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 1: 34-42. PMID 21293051 DOI: 10.18632/Oncotarget.106 |
0.379 |
|
| 2010 |
Gajdos V, Katsahian S, Beydon N, Abadie V, de Pontual L, Larrar S, Epaud R, Chevallier B, Bailleux S, Mollet-Boudjemline A, Bouyer J, Chevret S, Labrune P. Effectiveness of chest physiotherapy in infants hospitalized with acute bronchiolitis: a multicenter, randomized, controlled trial. Plos Medicine. 7: e1000345. PMID 20927359 DOI: 10.1371/Journal.Pmed.1000345 |
0.557 |
|
| 2010 |
Deslandes E, Chevret S. Joint modeling of multivariate longitudinal data and the dropout process in a competing risk setting: application to ICU data. Bmc Medical Research Methodology. 10: 69. PMID 20670425 DOI: 10.1186/1471-2288-10-69 |
0.786 |
|
| 2010 |
Dechartres A, Chevret S, Lambert J, Calvo F, Lévy V. Inclusion of patients with acute leukemia in clinical trials: a prospective multicenter survey of 1066 cases. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 22: 224-233. PMID 20627876 DOI: 10.1093/Annonc/Mdq336 |
0.586 |
|
| 2010 |
Azoulay E, Mokart D, Lambert J, Lemiale V, Rabbat A, Kouatchet A, Vincent F, Gruson D, Bruneel F, Epinette-Branche G, Lafabrie A, Hamidfar-Roy R, Cracco C, Renard B, Tonnelier JM, ... ... Chevret S, et al. Diagnostic strategy for hematology and oncology patients with acute respiratory failure: randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 182: 1038-46. PMID 20581167 DOI: 10.1164/Rccm.201001-0018Oc |
0.326 |
|
| 2010 |
Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, ... ... Chevret S, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 808-14. PMID 20048183 DOI: 10.1200/Jco.2009.23.2652 |
0.363 |
|
| 2010 |
Chevret S, Resche-Rigon M, Zohar S. Maximum-relevance weighted likelihood estimator: application to the continual reassessment method Statistics and Its Interface. 3: 177-183. DOI: 10.4310/Sii.2010.V3.N2.A5 |
0.495 |
|
| 2010 |
Ades L, Lebras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Delaunay J, Visanica S, Turlure P, Guerci A, Cabrol MP, Banos A, Blanc M, Vey N, Eclache V, ... Chevret S, et al. Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM) Blood. 116: 976-976. DOI: 10.1182/Blood.V116.21.976.976 |
0.329 |
|
| 2010 |
Rio B, Chevret S, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay J, Socie G, Ceballos P, Huynh A, Cornillon J, Francois S, Legrand F, Yakoub-Agha I, Michel G, et al. Reduced Intensity Conditioning Regimen Prior to Unrelated Cord Blood Transplantation In Patients with Acute Myeloid leukemia : Preliminary Analysis of a Prospective Phase II Multicentric Trial on Behalf of Societe Française De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord Blood. 116: 911-911. DOI: 10.1182/Blood.V116.21.911.911 |
0.316 |
|
| 2010 |
Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Vey N, Guerci A, Lamy T, Récher C, Mueller B, Tournilhac O, Pautas C, et al. Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases Blood. 116: 2171-2171. DOI: 10.1182/Blood.V116.21.2171.2171 |
0.322 |
|
| 2010 |
Boehrer S, Beyne-Rauzy O, Prebet T, Park S, Guerci A, Stamatoulas A, Chaury M, Jernival T, Sanhes L, Tertian G, Cheze S, Lim E, Choufi B, Caillot D, Wattel E, ... ... Chevret S, et al. Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone Blood. 116: 1880-1880. DOI: 10.1182/Blood.V116.21.1880.1880 |
0.366 |
|
| 2010 |
Ades L, Raffoux E, Chevret S, de Botton S, Guerci A, Pigneux A, Vey N, Lamy T, Huguet F, Muller B, Maloisel F, Deconinck E, Caillot D, Gratecos N, Sotto JJ, et al. Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group Blood. 116: 13-13. DOI: 10.1182/Blood.V116.21.13.13 |
0.337 |
|
| 2009 |
Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, Tournilhac O, de Botton S, Ifrah N, Cahn JY, Solary E, ... ... Chevret S, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 115: 1690-6. PMID 20018913 DOI: 10.1182/Blood-2009-07-233387 |
0.341 |
|
| 2009 |
Zohar S, Medioni J, Lebbé C, Avril MF, Kerob D, Eftekhari P, Driheme A, Lebras KC, Bruzzoni-Giovanelli H, Levy V, Chevret S, Calvo F. Interest in an original methodology to define the optimal dosage of interferon-alpha-2a in metastatic melanoma patients. Melanoma Research. 19: 379-84. PMID 19858763 DOI: 10.1097/Cmr.0B013E3283281042 |
0.698 |
|
| 2009 |
Cassinat B, de Botton S, Kelaidi C, Ades L, Zassadowski F, Guillemot I, Schlageter MH, Raffoux E, Harousseau JL, Legrand O, Escoffre-Barbe M, Reman O, Gardembas M, Himberlin C, Cahn JY, ... ... Chevret S, et al. When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). Leukemia Research. 33: 1178-82. PMID 19167754 DOI: 10.1016/J.Leukres.2008.12.010 |
0.333 |
|
| 2009 |
Gandemer V, Auclerc MF, Perel Y, Vannier JP, Le Gall E, Demeocq F, Schmitt C, Piguet C, Stephan JL, Lejars O, Debre M, Jonveaux P, Cayuela JM, Chevret S, Leverger G, et al. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study Bmc Cancer. 9: 14. PMID 19144139 DOI: 10.1186/1471-2407-9-14 |
0.315 |
|
| 2009 |
Merlin E, Zohar S, Jérôme C, Veyrat-Masson R, Marceau G, Paillard C, Auvrignon A, Le Moine P, Gandemer V, Sapin V, Halle P, Boiret-Dupré N, Chevret S, Deméocq F, Dubray C, et al. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit? Bone Marrow Transplantation. 43: 919-25. PMID 19104490 DOI: 10.1038/Bmt.2008.412 |
0.568 |
|
| 2009 |
Camps SM, Chevret S, Lévy V. How to use clinical vignettes in hematology--a pilot survey in the context of chronic lymphocytic leukemia. Leukemia Research. 33: 1328-34. PMID 19095303 DOI: 10.1016/J.Leukres.2008.11.008 |
0.542 |
|
| 2009 |
Hiance A, Chevret S, Lévy V. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial. Journal of Clinical Epidemiology. 62: 431-437.e2. PMID 19010642 DOI: 10.1016/J.Jclinepi.2008.04.009 |
0.58 |
|
| 2009 |
Sutton L, Neste EVD, Chevret S, Maloum K, Toumilhac O, Divine M, Leblond V, Corront B, Lepretre S, Eghbali H, Michallet M, Maloisel F, Bouabdallah K, Berthou C, Brice P, et al. Autologous Stem cell Transplantation (ASCT) in CLL. Results of a Phase III Randomized Multicenter Trial Blood. 114: 361-362. DOI: 10.1182/Blood.V114.22.878.878 |
0.374 |
|
| 2009 |
Ades L, Montesinos P, Chevret S, Vellenga E, Raffoux E, Rayon C, Díaz-Mediavilla J, Thomas X, Chevallier P, Rivas C, Guerci A, Amutio E, Huguet F, Arias J, Vey N, et al. Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups. Blood. 114: 845-845. DOI: 10.1182/Blood.V114.22.845.845 |
0.347 |
|
| 2009 |
Gardin C, Prébet T, Bouabdallah K, Caillot D, Guerci A, Raffoux E, Marolleau JP, Pautas C, Banos A, Himberlin C, Taksin A, Pigneux A, Thomas X, Jernival T, Vey N, ... ... Chevret S, et al. A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study. Blood. 114: 844-844. DOI: 10.1182/Blood.V114.22.844.844 |
0.32 |
|
| 2009 |
Resche-Rigon M, Robin M, Peffault de Latour R, Chevret S, Socie GP. Estimating the Causal Effect of Some Exposure From Nonrandomized Studies: The Example of Reduced Intensity Conditioning (RIC) in Hematological Diseases. Blood. 114: 3365-3365. DOI: 10.1182/Blood.V114.22.3365.3365 |
0.6 |
|
| 2008 |
Resche-Rigon M, Zohar S, Chevret S. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. Clinical Trials (London, England). 5: 595-606. PMID 19029208 DOI: 10.1177/1740774508098788 |
0.695 |
|
| 2008 |
Zohar S, Lian Q, Levy V, Cheung K, Ivanova A, Chevret S. Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. Clinical Trials (London, England). 5: 478-85. PMID 18827040 DOI: 10.1177/1740774508096653 |
0.7 |
|
| 2008 |
Brethon B, Yakouben K, Oudot C, Boutard P, Bruno B, Jérome C, Nelken B, de Lumley L, Bertrand Y, Dalle JH, Chevret S, Leblanc T, Baruchel A. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. British Journal of Haematology. 143: 541-7. PMID 18759760 DOI: 10.1111/J.1365-2141.2008.07370.X |
0.341 |
|
| 2008 |
Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 111: 4922-9. PMID 18250227 DOI: 10.1182/Blood-2007-11-125328 |
0.308 |
|
| 2008 |
Azoulay E, Mokart D, Rabbat A, Pene F, Kouatchet A, Bruneel F, Vincent F, Hamidfar R, Moreau D, Mohammedi I, Epinette G, Beduneau G, Castelain V, de Lassence A, Gruson D, ... ... Chevret S, et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. Critical Care Medicine. 36: 100-7. PMID 18090351 DOI: 10.1097/01.Ccm.0000295590.33145.C4 |
0.303 |
|
| 2008 |
Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, Vellenga E, Guerci A, Pigneux A, Huguet F, Rayon C, Stoppa AM, de la Serna J, Cahn JY, Meyer-Monard S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 111: 1078-84. PMID 17975017 DOI: 10.1182/Blood-2007-07-099978 |
0.379 |
|
| 2008 |
Katsahian S, Latouche A, Mary JY, Chevret S, Porcher R. Practical methodology of meta-analysis of individual patient data using a survival outcome. Contemporary Clinical Trials. 29: 220-30. PMID 17884735 DOI: 10.1016/J.Cct.2007.08.002 |
0.756 |
|
| 2008 |
Kiladjian J, Chevret S, Abgrall J, Chait Y, Briere J. Risk Stratification for Survival and Clonal Progression in Essential Thrombocythemia (ET): Result of a Prospective Study of 108 Patients with Very Long Term Follow up. Blood. 112: 1747-1747. DOI: 10.1182/Blood.V112.11.1747.1747 |
0.324 |
|
| 2008 |
Kiladjian J, Chevret S, Dosquet C, Fenaux P, Chomienne C, Rain J. Long-Term Outcome in Polycythemia Vera (PV): Final Analysis of a Randomized Trial Comparing Hydroxyurea (HU) to Pipobroman (Pi). Blood. 112: 1746-1746. DOI: 10.1182/Blood.V112.11.1746.1746 |
0.367 |
|
| 2008 |
Renneville A, Castaigne S, Chevret S, Llopis L, Philippe N, Nibourel O, Hayette S, Cayuela J, Naguib D, Gachard N, Bories D, Bastard C, Merabet F, Pautas C, Terré C, et al. Incidence and Prognostic Impact of Gene Mutations in Older Patients with AML Treated in the ALFA-9801 Study. Blood. 112: 1525-1525. DOI: 10.1182/Blood.V112.11.1525.1525 |
0.335 |
|
| 2008 |
Thepot S, Gardin C, Chevret S, de Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Vey N, Lamy T, Huguet F, Vekhoff A, Meyer S, Rayon C, Pabst T, et al. Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL Blood. 112: 139-139. DOI: 10.1182/Blood.V112.11.139.139 |
0.337 |
|
| 2008 |
Karlin L, Arnulf B, Chevret S, Robin M, Latour RPd, Malphettes M, Kabbara N, Asli B, Adès L, Rocha V, Fermand J, Socié G. Use of the Propensity Score Matching Method to Reduce Recruitment Bias in Observational Studies: Application to the Estimation of Survival Benefit of Non-Myeloablative Allogeneic Transplantation In Patients with Multiple Myeloma Relapsing after a First Autologous Transplantation. Blood. 112: 1133-1133. DOI: 10.1182/Blood.V112.11.1133.1133 |
0.311 |
|
| 2007 |
Gajdos P, Chevret S. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin. Annals of the New York Academy of Sciences. 1132: 271-5. PMID 18096850 DOI: 10.1196/Annals.1405.001 |
0.332 |
|
| 2007 |
Deslandes E, Chevret S. Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia. Statistics in Medicine. 26: 5411-21. PMID 18058850 DOI: 10.1002/Sim.3142 |
0.788 |
|
| 2007 |
Zohar S, Chevret S. Recent developments in adaptive designs for Phase I/II dose-finding studies. Journal of Biopharmaceutical Statistics. 17: 1071-83. PMID 18027217 DOI: 10.1080/10543400701645116 |
0.605 |
|
| 2007 |
Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, Vannier JP, Yakouben K, Thuret I, Bordigoni P, Fischer A, Lutz P, Stephan JL, Dhedin N, Plouvier E, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease Blood. 110: 2749-2756. PMID 17606762 DOI: 10.1182/Blood-2007-03-079665 |
0.303 |
|
| 2007 |
Bergeron A, Belle A, Chevret S, Ribaud P, Devergie A, Esperou H, Ades L, Gluckman E, Socié G, Tazi A. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplantation. 39: 547-53. PMID 17351647 DOI: 10.1038/Sj.Bmt.1705637 |
0.341 |
|
| 2007 |
Lecuyer L, Chevret S, Thiery G, Darmon M, Schlemmer B, Azoulay É. The ICU Trial: A new admission policy for cancer patients requiring mechanical ventilation Critical Care Medicine. 35: 808-814. PMID 17235261 DOI: 10.1097/01.Ccm.0000256846.27192.7A |
0.354 |
|
| 2007 |
Latouche A, Boisson V, Chevret S, Porcher R. Misspecified regression model for the subdistribution hazard of a competing risk. Statistics in Medicine. 26: 965-74. PMID 16755533 DOI: 10.1002/Sim.2600 |
0.654 |
|
| 2006 |
Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5703-10. PMID 17116939 DOI: 10.1200/Jco.2006.08.1596 |
0.347 |
|
| 2006 |
Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Turlure P, Reman O, Gardin C, Varet B, de Botton S, Pousset F, Farhat H, ... Chevret S, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia. 21: 66-71. PMID 17051246 DOI: 10.1038/Sj.Leu.2404434 |
0.355 |
|
| 2006 |
Katsahian S, Resche-Rigon M, Chevret S, Porcher R. Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution. Statistics in Medicine. 25: 4267-78. PMID 16960919 DOI: 10.1002/Sim.2684 |
0.691 |
|
| 2006 |
Lévy V, Zohar S, Bardin C, Vekhoff A, Chaoui D, Rio B, Legrand O, Sentenac S, Rousselot P, Raffoux E, Chast F, Chevret S, Marie JP. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. British Journal of Cancer. 95: 253-9. PMID 16847470 DOI: 10.1038/Sj.Bjc.6603265 |
0.692 |
|
| 2006 |
Lefrère F, Zohar S, Bresson JL, Chevret S, Mogenet A, Audat F, Durand-Zaleski I, Ghez D, Dal Cortivo L, Piesvaux P, Cavazzana-Calvo M, Varet B. A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. Haematologica. 91: 550-3. PMID 16585020 |
0.56 |
|
| 2006 |
Latouche A, Porcher R, Chevret S. A note on including time-dependent covariate in regression model for competing risks data. Biometrical Journal. Biometrische Zeitschrift. 47: 807-14. PMID 16450853 DOI: 10.1002/Bimj.200410152 |
0.637 |
|
| 2006 |
Tournoux C, Katsahian S, Chevret S, Levy V. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer. 106: 258-70. PMID 16397866 DOI: 10.1002/cncr.21613 |
0.682 |
|
| 2006 |
Resche-Rigon M, Azoulay E, Chevret S. Evaluating mortality in intensive care units: contribution of competing risks analyses. Critical Care (London, England). 10: R5. PMID 16356211 DOI: 10.1186/Cc3921 |
0.558 |
|
| 2006 |
Alberti C, Timsit JF, Chevret S. [Survival analysis - the log rank test]. Revue Des Maladies Respiratoires. 22: 829-32. PMID 16272989 DOI: 10.1016/S0761-8425(05)85644-X |
0.464 |
|
| 2006 |
Resche-Rigon M, Chevret S. Local influence for the subdistribution of a competing risk. Statistics in Medicine. 25: 1937-47. PMID 16158402 DOI: 10.1002/Sim.2354 |
0.534 |
|
| 2006 |
Alberti C, Timsit JF, Chevret S. [Survival analysis: how to manage censored data? The Kaplan-Meier's méthod]. Revue Des Maladies Respiratoires. 22: 333-7. PMID 16092173 DOI: 10.1016/S0761-8425(05)85488-9 |
0.479 |
|
| 2006 |
Macro M, Divine M, Uzunhan Y, Jaccard A, Bouscary D, Leblond V, Janvier M, Genet P, Castaigne S, Royer B, Allard C, Chevret S, Fermand J. Dexamethasone+Thalidomide (Dex/Thal) Compared to VAD as a Pre-Transplant Treatment in Newly Diagnosed Multiple Myeloma (MM): A Randomized Trial. Blood. 108: 57-57. DOI: 10.1182/Blood.V108.11.57.57 |
0.313 |
|
| 2006 |
Fermand J, Jaccard A, Macro M, Uzunhan Y, Allard C, Castaigne S, Divine M, Mariette X, Leblond V, Chevret S. A Randomized Comparison of Dexamethasone + Thalidomide (Dex/Thal) vs Dex + Placebo (Dex/P) in Patients (pts) with Relapsing Multiple Myeloma (MM). Blood. 108: 3563-3563. DOI: 10.1182/Blood.V108.11.3563.3563 |
0.307 |
|
| 2006 |
Katsahian S, Labopin M, Frassoni F, Rocha V, Chevret S. Persistent Centre Effect but Improvement of Leukemia-Free Survival of HLA Identical Hematopoietic Stem Cell Transplantation for Adults with AML in First CR in Europe over the Period 1987–2005 an Analysis on Behalf of the ALWP of EBMT. Blood. 108: 3027-3027. DOI: 10.1182/Blood.V108.11.3027.3027 |
0.608 |
|
| 2005 |
Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Attarian S, Chevret S. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: A randomized double-blind clinical trial Archives of Neurology. 62: 1689-1693. PMID 16286541 DOI: 10.1001/Archneur.62.11.1689 |
0.334 |
|
| 2005 |
Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9227-33. PMID 16275936 DOI: 10.1200/Jco.2005.03.0551 |
0.596 |
|
| 2005 |
Treluyer JM, Zohar S, Rey E, Hubert P, Iserin F, Jugie M, Lenclen R, Chevret S, Pons G. Minimum effective dose of midazolam for sedation of mechanically ventilated neonates. Journal of Clinical Pharmacy and Therapeutics. 30: 479-85. PMID 16164495 DOI: 10.1111/J.1365-2710.2005.00678.X |
0.578 |
|
| 2005 |
Lévy V, Katsahian S, Fermand JP, Mary JY, Chevret S. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine. 84: 250-60. PMID 16010209 DOI: 10.1097/01.Md.0000173272.71949.A1 |
0.72 |
|
| 2005 |
Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, Moriette G, Rey E, Treluyer JM. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. Journal of Clinical Pharmacy and Therapeutics. 30: 121-32. PMID 15811164 DOI: 10.1111/J.1365-2710.2005.00630.X |
0.539 |
|
| 2005 |
Lévy V, Morel P, Porcher R, Chevret S, Wattel E, Leblond V. Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis. Haematologica. 90: 279-81. PMID 15710594 |
0.539 |
|
| 2005 |
Alberti C, Brun-Buisson C, Chevret S, Antonelli M, Goodman SV, Martin C, Moreno R, Ochagavia AR, Palazzo M, Werdan K, Le Gall JR. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. American Journal of Respiratory and Critical Care Medicine. 171: 461-8. PMID 15531752 DOI: 10.1164/Rccm.200403-324Oc |
0.489 |
|
| 2005 |
Timsit JF, Chevret S, Alberti C. [Contingency tables and the chi2]. Revue Des Maladies Respiratoires. 21: 583-6. PMID 15292851 DOI: 10.1016/S0761-8425(04)71363-7 |
0.439 |
|
| 2005 |
Taksin AL, Raffoux E, de Revel T, Thomas X, Contentin N, Bouabdallah R, Pautas C, Bordessoulle D, Legrand O, Dombret H, Pousset F, Chevret S, Castaigne S. Fractionated Doses Mylotarg in First Relapsed AML Patients Is Effective and Safe: Results of a Prospective French Alfa Group Study. Blood. 106: 1850-1850. DOI: 10.1182/Blood.V106.11.1850.1850 |
0.346 |
|
| 2005 |
Gardin C, Chevret S, Charrin C, Thomas X, Bastard C, Lai J, Maarek O, de Botton S, Bordessoule D, Tilly H, de Revel T, Terre C, Preudhomme C, Bauters F, Michallet M, et al. ALFA-9000 Trial - An Analysis of Cytogenetic Subsets: Significant Long-Term Benefit of Early Induction Reinforcement Is Observed in CBF-AML Only. Blood. 106: 1842-1842. DOI: 10.1182/Blood.V106.11.1842.1842 |
0.352 |
|
| 2005 |
Timsit J, Alberti C, Chevret S. Le modèle de Cox Revue Des Maladies Respiratoires. 22: 1058-1064. DOI: 10.1016/S0761-8425(05)85739-0 |
0.445 |
|
| 2004 |
Katsahian S, Porcher R, Mary JY, Chevret S. The graft-versus-leukaemia effect after allogeneic bone-marrow transplantation: assessment through competing risks approaches. Statistics in Medicine. 23: 3851-63. PMID 15580602 DOI: 10.1002/Sim.1999 |
0.595 |
|
| 2004 |
Azoulay E, Thiéry G, Chevret S, Moreau D, Darmon M, Bergeron A, Yang K, Meignin V, Ciroldi M, Le Gall JR, Tazi A, Schlemmer B. The prognosis of acute respiratory failure in critically ill cancer patients. Medicine. 83: 360-70. PMID 15525848 DOI: 10.1097/01.Md.0000145370.63676.Fb |
0.334 |
|
| 2004 |
Latouche A, Porcher R, Chevret S. Sample size formula for proportional hazards modelling of competing risks. Statistics in Medicine. 23: 3263-74. PMID 15490425 DOI: 10.1002/Sim.1915 |
0.652 |
|
| 2004 |
Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, de Revel T, Simon M, Dupriez B, Renoux M, Janvier M, Micléa JM, Thomas X, Bastard C, Preudhomme C, et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 104: 2467-74. PMID 15142880 DOI: 10.1182/Blood-2003-10-3561 |
0.352 |
|
| 2004 |
Fenaux P, Chevret S, de Botton S. Treatment of older adults with acute promyelocytic leukaemia. Best Practice & Research. Clinical Haematology. 16: 495-501. PMID 12935965 DOI: 10.1016/S1521-6926(03)00044-6 |
0.334 |
|
| 2004 |
Filion A, Loiseau P, Rocha V, Tamouza R, Chevret S, Busson M, Esperou H, Traineau R, Socie G, Gluckman E, Charron D. Decreased Transplant Related Mortality and Better Survival in HLA Matched (12/12 A, B, C, DRB1, DQB1, DPB1) Unrelated Bone Marrow Transplants. Blood. 104: 977-977. DOI: 10.1182/Blood.V104.11.977.977 |
0.311 |
|
| 2004 |
Boulanger E, Gerard L, Gabarre J, Molina J, Rapp C, Abino J, Cadranel J, Chevret S, Oksenhendler E. Prognostic Factors and Outcome of Human Herpesvirus 8 (KSHV/HHV-8)-Associated Primary Effusion Lymphoma (PEL) in Patients with AIDS. Blood. 104: 2286-2286. DOI: 10.1182/Blood.V104.11.2286.2286 |
0.338 |
|
| 2003 |
Zohar S, Latouche A, Taconnet M, Chevret S. Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Computer Methods and Programs in Biomedicine. 72: 117-25. PMID 12941516 DOI: 10.1016/S0169-2607(02)00120-7 |
0.746 |
|
| 2003 |
Alberti C, Métivier F, Landais P, Thervet E, Legendre C, Chevret S. Improving estimates of event incidence over time in populations exposed to other events: application to three large databases. Journal of Clinical Epidemiology. 56: 536-45. PMID 12873648 DOI: 10.1016/S0895-4356(03)00058-1 |
0.526 |
|
| 2003 |
Cordonnier C, Chevret S, Legrand M, Rafi H, Dhédin N, Lehmann B, Bassompierre F, Gluckman E. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Annals of Internal Medicine. 139: 8-18. PMID 12834313 DOI: 10.7326/0003-4819-139-1-200307010-00007 |
0.319 |
|
| 2003 |
Zohar S, Chevret S. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design. Journal of Biopharmaceutical Statistics. 13: 87-101. PMID 12635905 DOI: 10.1081/Bip-120017728 |
0.617 |
|
| 2003 |
Bruneel F, Hocqueloux L, Alberti C, Wolff M, Chevret S, Bédos JP, Durand R, Le Bras J, Régnier B, Vachon F. The clinical spectrum of severe imported falciparum malaria in the intensive care unit: report of 188 cases in adults. American Journal of Respiratory and Critical Care Medicine. 167: 684-9. PMID 12411286 DOI: 10.1164/Rccm.200206-631Oc |
0.51 |
|
| 2002 |
Porcher R, Lévy V, Chevret S. Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint. Controlled Clinical Trials. 23: 650-61. PMID 12505243 DOI: 10.1016/S0197-2456(02)00239-8 |
0.588 |
|
| 2002 |
Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, Hachulla E, Philippe P, Sibilia J, Rabian C, Chevret S, Gluckman E. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. British Journal of Haematology. 119: 726-39. PMID 12437652 DOI: 10.1046/J.1365-2141.2002.03895.X |
0.609 |
|
| 2002 |
Timsit JF, Fosse JP, Troché G, De Lassence A, Alberti C, Garrouste-Orgeas M, Bornstain C, Adrie C, Cheval C, Chevret S. Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Critical Care Medicine. 30: 2003-13. PMID 12352033 DOI: 10.1097/00003246-200209000-00009 |
0.503 |
|
| 2002 |
Raschilas F, Wolff M, Delatour F, Chaffaut C, De Broucker T, Chevret S, Lebon P, Canton P, Rozenberg F. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 35: 254-60. PMID 12115090 DOI: 10.1086/341405 |
0.336 |
|
| 2002 |
Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. The Cochrane Database of Systematic Reviews. CD001798. PMID 12076424 DOI: 10.1002/14651858.Cd001798 |
0.302 |
|
| 2002 |
Porcher R, Lévy V, Fermand JP, Katsahian S, Chevret S, Ravaud P. Evaluating high dose therapy in Multiple Myeloma: use of quality-adjusted survival analysis. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 11: 91-9. PMID 12018742 DOI: 10.1023/A:1015096313594 |
0.686 |
|
| 2002 |
Godeau B, Chevret S, Varet B, Lefrère F, Zini JM, Bassompierre F, Chèze S, Legouffe E, Hulin C, Grange MJ, Fain O, Bierling P. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial Lancet. 359: 23-29. PMID 11809183 DOI: 10.1016/S0140-6736(02)07275-6 |
0.322 |
|
| 2002 |
Fartoukh M, Azoulay E, Galliot R, Le Gall JR, Baud F, Chevret S, Schlemmer B. Clinically documented pleural effusions in medical ICU patients: how useful is routine thoracentesis? Chest. 121: 178-84. PMID 11796448 DOI: 10.1378/Chest.121.1.178 |
0.309 |
|
| 2002 |
Mahé C, Chevret S. Analysis of recurrent failure times data: should the baseline hazard be stratified? Statistics in Medicine. 20: 3807-15. PMID 11782035 DOI: 10.1002/Sim.909 |
0.717 |
|
| 2001 |
Azoulay E, Fartoukh M, Similowski T, Galliot R, Soufir L, Le Gall JR, Chevret S, Schlemmer B. Routine exploratory thoracentesis in ICU patients with pleural effusions: results of a French questionnaire study. Journal of Critical Care. 16: 98-101. PMID 11689765 DOI: 10.1053/Jcrc.2001.28784 |
0.301 |
|
| 2001 |
Pellet C, Chevret S, Blum L, Gauvillé C, Hurault M, Blanchard G, Agbalika F, Lascoux C, Ponscarme D, Morel P, Calvo F, Lebbé C. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. The Journal of Investigative Dermatology. 117: 858-63. PMID 11676823 DOI: 10.1046/J.0022-202X.2001.01465.X |
0.311 |
|
| 2001 |
Cassinat B, Chevret S, Zassadowski F, Balitrand N, Guillemot I, Menot ML, Degos L, Fenaux P, Chomienne C. In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. Blood. 98: 2862-4. PMID 11675363 DOI: 10.1182/Blood.V98.9.2862 |
0.347 |
|
| 2001 |
Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 98: 2319-25. PMID 11588025 DOI: 10.1182/Blood.V98.8.2319 |
0.336 |
|
| 2001 |
Zohar S, Chevret S. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Statistics in Medicine. 20: 2827-43. PMID 11568943 DOI: 10.1002/Sim.920 |
0.618 |
|
| 2001 |
Lévy V, Porcher R, Leblond V, Fermand JP, Cazin B, Maloisel F, Harousseau JL, Remenieras L, Guibon O, Chevret S. Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis. Leukemia. 15: 1466-70. PMID 11516109 DOI: 10.1038/Sj.Leu.2402221 |
0.59 |
|
| 2001 |
Lévy V, Zohar S, Porcher R, Chevret S. Alternate designs for conduct and analysis of phase I cancer trials. Blood. 98: 1275-6. PMID 11510472 DOI: 10.1182/Blood.V98.4.1275 |
0.699 |
|
| 2001 |
Timsit JF, Fosse JP, Troché G, De Lassence A, Alberti C, Garrouste-Orgeas M, Azoulay E, Chevret S, Moine P, Cohen Y. Accuracy of a composite score using daily SAPS II and LOD scores for predicting hospital mortality in ICU patients hospitalized for more than 72 h. Intensive Care Medicine. 27: 1012-21. PMID 11497133 DOI: 10.1007/S001340100961 |
0.495 |
|
| 2001 |
Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. Journal of Clinical Epidemiology. 54: 747-54. PMID 11438417 DOI: 10.1016/S0895-4356(00)00359-0 |
0.594 |
|
| 2001 |
Azoulay E, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C, Chevret S, Le Gall JR, Brochard L, Schlemmer B. Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Critical Care Medicine. 29: 519-25. PMID 11373414 DOI: 10.1097/00003246-200103000-00009 |
0.518 |
|
| 2001 |
Mahé C, Chevret S. Estimating regression parameters and degree of dependence for multivariate failure time data. Biometrics. 55: 1078-84. PMID 11315051 DOI: 10.1111/J.0006-341X.1999.01078.X |
0.691 |
|
| 2001 |
Oksenhendler E, Gerard L, Dubreuil ML, Levy Y, Matheron S, Cazals-Hatem D, Chevret S, Clauvel JP. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma. Leukemia & Lymphoma. 39: 87-95. PMID 10975387 DOI: 10.3109/10428190009053542 |
0.334 |
|
| 2000 |
De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: Results of APL 93 trial British Journal of Haematology. 111: 801-806. PMID 11122141 DOI: 10.1046/J.1365-2141.2000.02442.X |
0.328 |
|
| 2000 |
Chevret S, Leporrier M, Chastang C. Measures of treatment effectiveness on tumour response and survival: a multi-state model approach. Statistics in Medicine. 19: 837-48. PMID 10734287 DOI: 10.1002/(Sici)1097-0258(20000330)19:6<837::Aid-Sim394>3.0.Co;2-3 |
0.323 |
|
| 2000 |
Garrouste-Orgeas M, Chevret S, Mainardi JL, Timsit JF, Misset B, Carlet J. A one-year prospective study of nosocomial bacteraemia in ICU and non-ICU patients and its impact on patient outcome. The Journal of Hospital Infection. 44: 206-13. PMID 10706804 DOI: 10.1053/Jhin.1999.0681 |
0.335 |
|
| 2000 |
de Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A, Fey M, Rayon C, Huguet F, Sotto J, Gardin C, Cony Makhoul P, Travade P, Solary E, Fegueux N, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial British Journal of Haematology. 111: 801-806. DOI: 10.1111/J.1365-2141.2000.02442.X |
0.311 |
|
| 1999 |
Poynard T, Daurat V, Chevret S, Moussalli J, Degos F, Bailly F, Borotto E, Buffet C, Bartolomei-Portal I, Richardet JP, Riachi G, Calmus Y, Bréchot C, Vidaud M, Olivi M, et al. A short induction regimen of interferon-α is not effective for treatment of relapse in chronic hepatitis C: a randomized trial Journal of Viral Hepatitis. 6: 381-386. PMID 10607254 DOI: 10.1046/J.1365-2893.1999.00170.X |
0.317 |
|
| 1999 |
Mahé C, Chevret S. Estimation of the treatment effect in a clinical trial when recurrent events define the endpoint. Statistics in Medicine. 18: 1821-9; discussion 1. PMID 10407253 DOI: 10.1002/(Sici)1097-0258(19990730)18:14<1821::Aid-Sim219>3.0.Co;2-O |
0.714 |
|
| 1999 |
Le Corfec E, Chevret S, Costagliola D. Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics. Statistics in Medicine. 18: 1803-17; discussion . PMID 10407251 DOI: 10.1002/(Sici)1097-0258(19990730)18:14<1803::Aid-Sim217>3.0.Co;2-Q |
0.313 |
|
| 1999 |
Bédos JP, Dumoulin JL, Gachot B, Veber B, Wolff M, Régnier B, Chevret S. Pneumocystis carinii pneumonia requiring intensive care management: survival and prognostic study in 110 patients with human immunodeficiency virus. Critical Care Medicine. 27: 1109-15. PMID 10397214 DOI: 10.1097/00003246-199906000-00030 |
0.324 |
|
| 1999 |
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto J, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, et al. A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia Blood. 94: 1192-1200. DOI: 10.1182/Blood.V94.4.1192.416K07_1192_1200 |
0.339 |
|
| 1998 |
Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Naveau S, Bailly F, Chaumet-Riffaud P, Chastang C. Reinforced regiment of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomized trial Journal of Hepatology. 29: 224-232. PMID 9722203 DOI: 10.1016/S0168-8278(98)80007-X |
0.338 |
|
| 1998 |
Fermand J, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet J. High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial Blood. 92: 3131-3136. DOI: 10.1182/Blood.V92.9.3131 |
0.369 |
|
| 1998 |
Mahe C, Chevret S. Analysis of multivariate failure time data in a clinical trials: Estimation of overall treatment effect and strength of correlation Controlled Clinical Trials. 19: S42-S43. DOI: 10.1016/S0197-2456(98)80126-8 |
0.701 |
|
| 1997 |
Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Annals of Neurology. 41: 789-96. PMID 9189040 DOI: 10.1002/Ana.410410615 |
0.308 |
|
| 1997 |
Brugiatelli M, Claisse JF, Lenormand B, Morabito F, Callea V, Malloum K, Chevret S, Binet JL, Dighiero G, Travade P. Long-term clinical outcome of B-cell chronic lymphocytic leukaemia patients in clinical remission phase evaluated at phenotypic level. British Journal of Haematology. 97: 113-8. PMID 9136949 DOI: 10.1046/J.1365-2141.1997.9922637.X |
0.352 |
|
| 1997 |
Verdon R, Chevret S, Laissy JP, Wolff M. Tuberculous meningitis in adults: review of 48 cases. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 22: 982-8. PMID 8783697 DOI: 10.1093/Clinids/22.6.982 |
0.353 |
|
| 1997 |
Sébille V, Chevret S, Valleron A. Modeling the Spread of Resistant Nosocomial Pathogens in an Intensive-Care Unit Infection Control and Hospital Epidemiology. 18: 84-92. DOI: 10.1086/647560 |
0.313 |
|
| 1997 |
Mahe C, Timsit J, Chevret S. 49 Case-control design using multivariate generalization of the cox model: Application to central catheters related bacteremia Controlled Clinical Trials. 18. DOI: 10.1016/S0197-2456(97)91034-5 |
0.666 |
|
| 1996 |
Feydy A, Sibilia J, De Kerviler E, Zagdanski AM, Chevret S, Fermand JP, Brouet JC, Frija J. Chest high resolution CT in adults with primary humoral immunodeficiency. The British Journal of Radiology. 69: 1108-16. PMID 9135465 DOI: 10.1259/0007-1285-69-828-1108 |
0.301 |
|
| 1996 |
Lucet JC, Chevret S, Decré D, Vanjak D, Macrez A, Bédos JP, Wolff M, Regnier B. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 22: 430-6. PMID 8852958 DOI: 10.1093/Clinids/22.3.430 |
0.317 |
|
| 1996 |
Darras-Joly C, Chevret S, Wolff M, Matheron S, Longuet P, Casalino E, Joly V, Chochillon C, Bédos JP. Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with human immunodeficiency virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 23: 369-76. PMID 8842276 DOI: 10.1093/Clinids/23.2.369 |
0.319 |
|
| 1996 |
Timsit JF, Chevret S, Valcke J, Misset B, Renaud B, Goldstein FW, Vaury P, Carlet J. Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools. American Journal of Respiratory and Critical Care Medicine. 154: 116-23. PMID 8680666 DOI: 10.1164/Ajrccm.154.1.8680666 |
0.311 |
|
| 1996 |
Timsit J, Sebille V, Farkas J, Misset B, Martin J, Chevret S, Carlet J. Effect of subcutaneous tunneling on internal jugular catheter-related sepsis in critically ill patients: a prospective randomized multicenter study. Jama. 276: 1416-1420. DOI: 10.1001/Jama.1996.03540170060033 |
0.338 |
|
| 1994 |
Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest. 105: 1487-95. PMID 8181342 DOI: 10.1378/Chest.105.5.1487 |
0.324 |
|
| 1994 |
Raphael JC, Chevret S, Chastang C, Bouvet F, the French Multicentre Cooperative Group. Randomised trial of preventive nasal ventilation in Duchenne muscular dystrophy The Lancet. 343: 1600-1604. PMID 7911921 DOI: 10.1016/S0140-6736(94)93058-9 |
0.355 |
|
| 1993 |
Holzapfel L, Chevret S, Madinier G, Ohen F, Demingeon G, Coupry A, Chaudet M. Influence of long-term oro- or nasotracheal intubation on nosocomial maxillary sinusitis and pneumonia: results of a prospective, randomized, clinical trial. Critical Care Medicine. 21: 1132-8. PMID 8339576 DOI: 10.1097/00132586-199406000-00057 |
0.334 |
|
| 1993 |
Chevret S. The continual reassessment method in cancer phase I clinical trials: a simulation study. Statistics in Medicine. 12: 1093-108. PMID 8210815 DOI: 10.1002/Sim.4780121201 |
0.326 |
|
| 1993 |
Fermand J, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F, Mariette X, Brouet J. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients Blood. 82: 2005-2009. DOI: 10.1182/Blood.V82.7.2005.2005 |
0.355 |
|
| 1993 |
Oksenhendler E, Bierling P, Chevret S, Delfraissy J, Laurian Y, Clauvel J, Seligmann M. Splenectomy is safe and effective in human immunodeficiency virus- related immune thrombocytopenia [see comments] Blood. 82: 29-32. DOI: 10.1182/Blood.V82.1.29.Bloodjournal82129 |
0.301 |
|
| 1992 |
O'Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Statistics in Medicine. 10: 1647-64. PMID 1792460 DOI: 10.1002/Sim.4780101104 |
0.305 |
|
| 1992 |
Farkas JC, Liu N, Bleriot JP, Chevret S, Goldstein FW, Carlet J. Single- versus triple-lumen central catheter-related sepsis: a prospective randomized study in a critically ill population. The American Journal of Medicine. 93: 277-82. PMID 1524079 DOI: 10.1016/0002-9343(92)90233-2 |
0.318 |
|
| 1992 |
Fermand JP, Chevret S, Levy Y, Miclea JM, Tsapis A, Gerota J, Benbunan M, Brouet JC. The Role of Autologous Blood Stem Cells in Support of High-dose Therapy for Multiple Myeloma Hematology/Oncology Clinics of North America. 6: 451-462. DOI: 10.1016/S0889-8588(18)30356-3 |
0.301 |
|
| 1991 |
Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, Chevret S, Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. The American Review of Respiratory Disease. 144: 564-9. PMID 1832527 DOI: 10.1164/Ajrccm/144.3_Pt_1.564 |
0.335 |
|
| Show low-probability matches. |